Epic Bio is developing ultra-compact therapies to modulate gene expression and treat complex disease. Epigenetics play a key role in the regulation of which genes are expressed within a cell. By leveraging the epigenome, Epic has built their “mix and match” Gene Expression Modulation System (GEMS) platform that can combine epigenomic modulators to create therapies customized for specific disease indications. Part of their toolbox includes CasMINI, the smallest and most deliverable dCas protein to work in human cells. This offers Epic even greater potential for in vivo delivery and multigene disease treatment.

Epic Bio

 Epic Bio to Participate in the Solebury / BMO Fall Private Company Showcase 

‘The Light of Asia’: Jairam Ramesh’s new book is a biography of an epic bio-poem on the Buddha - Scroll.in

FDA Grants Orphan Drug Designation to EPI-321, Epic Bio's - GlobeNewswire

We’re excited to share that our CEO Amber Salzman will be speaking at the Financial Times US Pharma and Biotech Summit on Thursday, May 15 in New York.

Amber will join a CEO panel discussing how a new wave of #biotech leaders is driving innovation in cell and gene therapy, AI-powered drug discovery, and next-gen therapeutics, all while navigating today’s evolving regulatory and funding landscape.

🧬 Panel: Building the Next Generation of Biotech Companies
 📅 Thursday, May 15
 🕐 12:40 PM – 1:20 PM EDT
 📍 New York City

Joining Amber on stage:
 🔹 Glen Gowers, CEO & Co-founder, Basecamp Research
 🔹 Simon Kohl, Founder & CEO, Latent Labs
 🔹 Michael Curtis, President & CEO, eGenesis, Inc.

Learn more about the event: https://lnkd.in/ecSei2j

#biotech #pharma #genomics #healthtech #lifesciences #FinancialTimes #FTPharma

 Epic Bio Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th ... 

Epic Bio, Founded by CRISPR Pioneer, Launches to Revolutionize Genetic Medicine With Epigenetic Engineering - Business Wire

set its sights on

Epic Bio Presents New Data Highlighting Potential of - GlobeNewswire

 Epicrispr Biotechnologies: $68 Million (Series B) Raised For Developing Curative Therapies 

Epicrispr raises $68M, will start clinical trial of epigenetic editing for FSHD - Endpoints News


														Epicrispr banks $68M to test epigenetic editing on rare muscle disease													

Epic Bio - The Pharma Letter

We are looking forward to the Stifel Financial Corp. Healthcare conference next week. Please reach out to us at bd@epic-bio.com if you want to schedule a time to meet.  
 
#Epicrispr #biotechnology #EpigeneticEditing   

Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy Summit - GlobeNewswire

 Engineered nucleases and guide rna spacer sequences therefor, and compositions, … 

 Compositions, systems, and methods for treating familial hypercholesterolemia … 

 Epic Bio’s Post 

Home


														 
														
													

 Epic Bio to Present at the Upcoming CRISPR2.0 Conference 


														Epigenetic editing: a tunable CRISPR alternative													


														Six biotech spinouts you should watch out for this year													

Epic Bio’s EPI-321 named FDA orphan drug for FSHD - Muscular Dystrophy News

November is Alpha-1 Awareness Month.  
  
Alpha-1 has been identified in virtually all populations and is a progressive condition that has the potential to worsen over time, often leading to lung destruction that is commonly misdiagnosed as asthma or smoking-related COPD.  
  
At #Epicrispr, we are researching potential treatment options for Alpha-1 Antitrypsin Deficiency (A1AD) using our #epigenetic editing approach.   
  
Alpha-1 Foundation #Alpha1Awareness #A1FVW24 

 Epic Bio Reports Discovery of Exceptionally Durable Gene Activators and Creation of Machine Learning Algorithm to Design New Activators 

 EpicBio's EPI-321 presentation at ASGCT | Epic Bio posted on the topic 

 Engineered gene effectors, compositions, and methods of use thereof 

 Epic Bio, Founded by CRISPR Pioneer, Launches to Revolutionize Genetic Medicine With Epigenetic Engineering 


														Epigenomic CRISPR Startup Goes Big by Thinking Small													

Top Life Sciences Startups to Watch in 2023

Kite and Arcellx expand cell therapy partnership in deal worth over $285m - PMLiVE

Six Biotech spinouts you should watch out for this year

 Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy Summit 

Kite and Epic Bio announce cancer cell therapy collaboration agreement - PMLiVE

 Epic Bio on LinkedIn: A versatile CRISPR-Cas13d platform for multiplexed transcriptomic… 

 Epicrispr Biotechnologies Named Finalist in XPRIZE Healthspan Competition FSHD Bonus Prize 

Epic Bio to Present IND-Enabling Data Package for EPI-321 at FSHD International Research Congress - GlobeNewswire

 Engineered nucleases, compositions, and methods of use thereof 

In Pivotal Demonstration, Epic Bio Accomplishes Persistent Gene Activation with Single Administration - CRISPR Medicine News

 Systems and methods for regulating target genes 

Why Hong Kong's richest person is betting on a Peninsula biotech startup - The Business Journals


														Epigenetic Editing Explodes on the Heels of Gene Editing Success													

Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD - Business Wire


														Alexandra Collin de l’Hortet, PhD, on Evaluating Epigenetic Gene Therapy for the Treatment of FSHD													

Surabhi Godbole, a member of the #Epicrispr CMC team, delivered an oral presentation at Cell & Gene Therapy International Europe last week!  
  
Her insights on upstream manufacturing processes and process scale-up showcased how our leadership in #EpigeneticEditing spans not just scientific expertise but also innovative strategies for drug development and manufacturing—pivotal for bringing this technology to patients.  
  
#biotechnology


														Epicrispr: Epigenome editing via compact components													


														Promising Clinical Data Supports Clinical Initiation of Epicrispr's FSHD Therapy													

Big Pharma vet teams with former Doudna pupil to launch new epigenome startup - Endpoints News

Kite enlists Epic Bio to apply epigenetic editing in creating next-gen CAR-T cells - Endpoints News


														CRISPR co-inventor’s Epicrispr launches with $55M series A													

Epic Bio makes gene therapies by editing the epigenome - Labiotech.eu


														Epigenome Editing Companies Mark Preclinical Progress													

 Epic Bio to Participate in the BMO Virtual Spotlight Series 


														Kite enlists Epicrispr to apply epigenetic editing in creating next-gen CAR-T cells													

Epic Bio Presents New Data on Epigenetic Editing Platform at CRISPR Frontiers Conference - CRISPR Medicine News


														Big Pharma vet teams with former Doudna pupil to launch new epigenome startup													

Epic Bio launches with $55 million financing - The Pharma Letter

 Systems and methods for regulating aberrant gene expressions 

We’ve developed a suite of super-small Cas molecules for Epicrispr’s #EpigeneticEditing therapies. And they’re not limited to just that application: As a new article by Revvity appearing in Technology Networks points out, smaller nucleases with better safety profiles and wider genomic reach could be beneficial across many types of genetic medicines. 
 
Recent studies by our partners at Revvity find that our deactivated Cas ONYX (dCasONYX), combined with their Pin-point #baseediting system, can drive efficient base editing in vivo. Because dCasONYX doesn’t cut or nick the DNA, it sidesteps some safety issues with traditional Cas nucleases. And because dCasONYX is derived from archaea, an ancient type of microbe humans hardly ever encounter, people have exceptionally low pre-existing immunity.  
  
Check out the article here, and if you’re attending #ESGCT2024 this week, stop by our posters to learn more about our hypercompact Cas proteins. 
 
https://lnkd.in/eEnh9Bke 
 
#epicrispr 

 Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer 

 Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study 

 Epic Bio achieves persistent gene activation using GEMS platform 


														Epicrispr makes gene therapies by editing the epigenome													

This is Epic: Epigenomic CRISPR Startup Goes Big by Thinking Small - Genetic Engineering & Biotechnology News

🎤 Happening today at SynBioBeta!

We’re excited to see Melanie Silvis, Senior Scientist, join Ryan Clarke, Co-founder & CTO of Syntax Bio, on stage today at #SynBioBeta25 to explore how synthetic biology, epigenetic regulation, and cell reprogramming are reshaping the future of medicine.

At Epicrispr, we’re unlocking the body’s own epigenetic code to treat complex, previously untreatable diseases without cutting DNA. We're thrilled to be part of this important conversation on next-gen biotech innovation and how we can make breakthrough therapies more scalable, precise, and accessible.

Thanks to Cellino for supporting this discussion and to the entire #SynBioBeta2025 community for pushing the boundaries of what’s possible.

Sharing the full agenda: 

https://lnkd.in/eQXs_K-J

#Epigenetics #GeneRegulation #CellTherapy #CellAndGeneTherapy #BiotechInnovation #NextGenTherapies

Neurosurgeon pulled off cruise after fake bio-terrorism Tweet - Daily Mail

 Epic Bio to Present at the Upcoming Annual European Society ... 

 $68 million for Epicrispr’s development of FSHD candidate 

[Rebroadcast] Epigenetic editing – the power of CRISPR without cutting DNA - Labiotech.eu

Alexandra Collin de l’Hortet, PhD, on Evaluating Epigenetic Gene Therapy for the Treatment of FSHD - CGTLive™

 Epic Bio Presents New Data Highlighting Potential of EPI-321 for FSHD and Epigenetic Editing Platform Leadership at ... 

Epicrispr Biotechnologies Presents Data on Powerful Gene Reactivation with GEMS Epigenetic Editors at ESGCT - GlobeNewswire

 Kite and Epic Bio Announce Collaboration to Develop New ... 

 Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability 

We’re excited to announce a partnership with Springbok Analytics to bring AI-driven muscle MRI imaging and analysis into our first-in-human clinical trial of EPI-321, a potential first-in-class epigenetic therapy for FSHD. 🧬🧬

Springbok’s AI imaging technology segments and quantifies dozens of muscles from MRI scans, analyzing key biomarkers like volume, fat infiltration, and inflammation, delivering high-resolution, actionable insights within hours to support early clinical decisions.

Proud to be working with innovators who share our mission to bring curative therapies to patients.

Read the release:

https://lnkd.in/eR-aedcS

#FSHD #ClinicalTrials #AI #Biotech #RareDisease #Epigenetics #MRI #Imaging

 Epigenetic editing – the power of CRISPR without cutting DNA 


														A New Tomato And A Potential New Class Of Medicine Share This Fascinating Technology													

Epic Bio to Present Preclinical Data at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting - GlobeNewswire

We’re excited to announce five presentations at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, being held May 15-17, 2025, in New Orleans, Louisiana. 

The presentations will highlight the company’s progress across key areas, including our lead epigenetic therapeutic candidate EPI-321, novel Cas effectors for epigenome engineering, and innovations in compact modular epigenetic activators.

Read the release:

https://lnkd.in/ek4vDuk6

#ASGCT25 #FSHD


                Epicrispr exploring AI muscle-imaging biomarker in muscular dystrophy study
              

An Epic in miniature: CRISPR pioneer's startup reels in $55M to use tiny Cas for epigenetic engineering - Fierce Biotech

 Epic Bio to Participate in a Fireside Chat at the Canaccord Genuity Genetic Medicine for Generalists 

 Epic Bio to Present IND-Enabling Data Package for EPI-321 at FSHD International Research Congress 

We’re excited to share that Epicrispr Biotechnologies has been named a Finalist in the XPRIZE Healthspan FSHD Bonus Prize and awarded a $250,000 Milestone Award.

We’re one of eight teams globally recognized for bold, science-driven solutions to #FSHD, one of the most common forms of muscular dystrophy.

Our lead program targets DUX4, the gene at the root of FSHD using our epigenetic modulation platform to control gene expression without cutting DNA.

Proud of our team and grateful to XPRIZE, Hevolution Foundation and SOLVE FSHD for recognizing our mission to degelop curative therapies for neuromuscular diseases. 

Epicrispr will be honored at the XPRIZE Healthspan Awards Ceremony and Investor Summit in New York City, taking place May 12–14, 2025.

Read the release:

https://lnkd.in/eENg9E5K

#XPRIZE #FSHD #Healthspan #Epicrispr #Biotech #Epigenetics

Press Release Service: Epic Bio Named a “Fierce 15” Company by Fierce Biotech - CRISPR Medicine News


														Daniel Hart, PhD, on CRISPR-Mediated In Vivo Epigenomic Activation													

CRISPR Pioneer Goes Small to Transform Genetic Medicine with Epigenetic Engineering - BioSpace

 The Week’s 10 Biggest Funding Rounds: Monolith Closes Monolithic Round; Pico Picks Up $200M 

Epic Bio Announces Robust Slate of Presentations at the - GlobeNewswire

We’re excited to be at World Muscle Society’s #WMS2024 this week to present some of the robust preclinical data on EPI-321, our epigenetic editing candidate for the treatment of #FSHD. Our poster will be available here once the presentation concludes: https://lnkd.in/eFMKkJj5  
 
#epicrispr #epigeneticediting  

 Epic Bio

Epigenetic editing – the power of CRISPR without cutting DNA - Labiotech.eu

 Kite joins forces with Epic Bio to develop new cancer therapies 

Excited to share that Melanie Silvis, Senior Scientist at Epicrispr, will be speaking at #SynBioBeta2025 this week! 

Catch her on Wednesday, May 7 from 4:30–5:15pm in the breakout session:
 “The Living Future: How SynBio, Genomics, and Regenerative Medicine are Transforming Human Health”

She’ll be joining Ryan Clarke from Syntax Bio to explore how synthetic biology, epigenetic regulation, and cell reprogramming are unlocking new frontiers in the treatment of complex diseases.

Looking forward to connecting at SynBioBeta!

Learn more about the conference: 

https://lnkd.in/e6rdmrBK

 #SynBioBeta25 #Epicrispr #Epigenetics #Biotech 

 Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD 

The Epicrispr team is on the ground at #ESGCT2024 and excited to present 3 posters, including new data on a novel epigenetic modulator we developed for gene reactivation.  
 
The ability to reactivate epigenetically silenced genes could open new avenues for #EpigeneticEditing therapies. And Epicrispr’s data show that by combining this modulator with our existing activators, the gene activation is incredibly robust. 
 
Learn more about our ESGCT presentations in our press release: https://lnkd.in/ez6wiCP2 
 
#biotechnology #EpigeneticEditing  
#epicrispr 

This week Epicrispr scientific founder Lei (Stanley) Qi is a featured keynote speaker at AIChE - American Institute of Chemical Engineers International Conference on #CRISPR Technologies, alongside George Church and other luminaries. Stanley’s talk, on precision #EpigeneticEditing, details some of the pioneering science that formed the basis of our field-leading GEMS platform to create epigenetic editing therapies. 
  
See the full conference agenda at https://lnkd.in/eR2Cdfmk  
  
#biotechnology #genetherapy #CRISPR2024 #epicrispr #epigeneticediting

As 2024 comes to a close, we’re reflecting on an incredible year at #Epicrispr. Our outstanding team has worked tirelessly to advance our mission and share our game-changing breakthroughs with patients suffering from FSHD and with the world.

This year our scientists presented exciting new data at American Society of Gene & Cell Therapy (ASGCT), European Society of Gene and Cell Therapy (ESGCT), the World Muscle Society Annual Congress, Cold Spring Harbor Laboratory’s Genome Engineering CRISPR Frontiers, among others—check out all our presentations at https://bit.ly/3ZHNvgy and all of our press releases at https://bit.ly/4iXhhXx.

We also treasured the opportunity to connect with the FSHD community at the FSHD Society International Research Congress in Colorado, the New England FSHD 360 Conference in Massachusetts, and the Friends of FSH Research meeting in Washington. 

Happy holidays from all of us at Epicrispr!

Epic Bio Presents Compelling Preclinical Data Supporting Clinical Initiation of EPI-321 for FSHD - GlobeNewswire

Kite joins forces with Epic Bio to develop new cancer therapies - The Pharma Letter

Epic Bio

Business:

Drug notes:

About: